

1 **Haematological parameters and plasma levels of 8-iso-prostaglandin F2 $\alpha$  in malaria-sickle**  
2 **cell co-morbidity: A cross sectional study**

3 Enoch Aninagyei <sup>1¶\*</sup>, Emmanuel Doku Tetteh <sup>2&</sup>, Josephine Banini <sup>3</sup>, Emmanuel Nani <sup>4</sup>, Patrick  
4 Adu<sup>5¶</sup>, Richard K. D. Ephraim <sup>5¶</sup>, Alexander Egyir-Yawson <sup>1&</sup>, Desmond Omane Acheampong <sup>1¶</sup>

5 <sup>1</sup>Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast,  
6 Cape Coast, Ghana

7 <sup>2</sup>School of Public Health, University of Ghana, Legon, Accra

8 <sup>3</sup>Ashaiman Polyclinic, Ashaiman, Ghana

9 <sup>4</sup>Ada East District Hospital, Ada, Ghana

10 <sup>5</sup>Department of Medical Laboratory Technology, School of Allied Health Sciences, University of  
11 Cape Coast, Cape Coast, Ghana

12

13 **\*Corresponding authors:**

14 [enochaninagyei@yahoo.com](mailto:enochaninagyei@yahoo.com) (AE), [dacheampong@ucc.edu.gh](mailto:dacheampong@ucc.edu.gh) (AOD)

15

16

17

18

19

20

21

## 22 **Abstract**

### 23 **Introduction**

24 Malaria and sickle cell disease (SCD) co-morbidity have previously been reported in Ghana.  
25 However, there is paucity of data on haematological profiles and oxidative stress in co-  
26 morbidity states. This study identified novel inflammatory biomarkers associated with malaria  
27 in SCD and analyzed the levels of 8-iso-prostaglandin F<sub>2</sub>α oxidative stress biomarker in malaria-  
28 SCD co-morbidity in Ghanaian patients.

### 29 **Methods**

30 Blood (5ml) was collected from malaria patients into K<sub>3</sub>-EDTA tube. Malaria parasites speciation  
31 and quantification were then done according WHO guidelines. All eligible samples were assayed  
32 for haematological profile, sickle cell phenotyping, infectious markers (hepatitis B, hepatitis C,  
33 syphilis and HIV 1&2) and plasma levels of 8-epi-prostaglandin F<sub>2</sub>α. .

34

### 35 **Results**

36 Prevalence of malaria in SCD (malaria-SCD) was 13.4% (45/335). Male: female ratio was 0.8:1  
37 ( $X^2=1.43$ ,  $p=0.231$ ). Mean ages for malaria in normal haemoglobin type (malaria-HbAA) and  
38 malaria-SCD were  $12.79\pm 4.91$  and  $11.56\pm 3.65$  years respectively ( $p=0.048$ ). Geometric mean of  
39 parasite density was higher in malaria-HbAA (20394 parasites/ $\mu$ l vs. 9990 parasites/ $\mu$ l,  $p=0.001$ )  
40 whilst mean body temperature was higher in malaria-SCD ( $39.0\pm 0.87^\circ\text{C}$  vs.  $37.9\pm 1.15^\circ\text{C}$ ,  
41  $p=0.001$ ). Mean leukocytes, lymphocytes, eosinophils, monocytes, platelets and platelet indices  
42 values were significantly elevated in malaria-SCD. Significant reduction in RBC and RBC indices

43 in malaria-SCD were also observed. Eosinophils-to-basophils ratio (EBR) and monocytes-to-  
44 basophils ratio (MBR) were novel cellular inflammatory biomarkers which could predict malaria  
45 in SCD. The sensitivities of cut-off values of EBR>14, MBR>22 and combined use of EBR>14 and  
46 MBR>22 were 79.55%, 84.09% and 91.11% respectively. Mean 8-iso-prostaglandin F2 $\alpha$  was  
47 338.1pg/ml in malaria-HbAA and 643.8pg/ml in malaria-SCD ( $p=0.001$ ). 8-iso-prostaglandin F2 $\alpha$   
48 correlated with parasite density ( $r=0.787$ ,  $p=0.001$ ), temperature ( $r=0.566$ ,  $p=0.001$ ) and  
49 leucocytes ( $r=0.573$ ,  $p=0.001$ ) and negatively correlated with RBC ( $r=-0.476$ ,  $p=0.003$ ),  
50 haemoglobin ( $r=-0.851$ ,  $p=0.001$ ) and haematocrit ( $r=-0.735$ ,  $p=0.001$ ).

51

## 52 **Conclusion**

53 *Plasmodium falciparum* parasitaemia increases oxidative damage and causes derangement  
54 haematological parameters. Cut of values of EBR>14 and MBR>22 could predict malaria in SCD.

55 **Keywords:** 8-epi-prostaglandin F2 $\alpha$ , oxidative stress, haematological profile, malaria-SCD co-  
56 morbidity, eosinophils-to-basophils ratio, monocytes-to-basophils ratio

57

58

## 59 **Introduction**

60 The asexual stages of *Plasmodium falciparum* are intra-erythrocytic thus inducing  
61 hematological alterations such as anemia, thrombocytopenia and neutrophilia [1-4]. Parasites  
62 density influence severity of the hematological changes. These changes depend on factors such

63 as level of malaria endemicity, presence of haemoglobinopathies, nutritional status and level of  
64 malaria immunity [5, 6]. Malaria is meso-endemic in Ghana with recent nationwide prevalence  
65 of 43.4% [7]. Sickle cell disease (SCD) resulting from two haemoglobin S (HbS) haplotypes  
66 (HbSS) and heterozygote sickle cell phenotype resulting from one HbS haplotype and one  
67 haemoglobin C (HbC) haplotype (HbSC) is also prevalent in Ghana [8]. Sickle cell haplotype HbS  
68 leads to polymerization of deoxygenated sickle haemoglobin within inelastic red blood cells  
69 which cause occlusion of microvasculature, resulting in acute complications, chronic organ  
70 damage, high rate of morbidity and mortality [9]. These mechanisms have adverse effect on the  
71 quality and quantity of formed blood cells in affected individuals. SCD has been found to be  
72 associated with anemia, low RBC count, low packed cell volume (PCV), low mean cell volume  
73 (MCV), low mean cell hemoglobin (MCH) [10, 11] and leukocytosis [12]. The trends in the  
74 haematological profiles associated with SCD and malaria are similar. There is evidence of  
75 altered hematopoiesis which affect all the three hematological cell lines in SCD and malaria.

76 Oxidative stress is the overproduction of free radicals beyond the physiological detoxification  
77 ability of the body [13]. A principal consequence of Plasmodium infections is the development  
78 of anemia [14]. Malaria infections release reactive oxygen species (ROS) as a result of activation  
79 of the immune system of the body. Plasmodium infections and sickle cell disease are associated  
80 with oxidative stress due to production of ROS which result in haemoglobin degradation [15-  
81 17]. Oxidative stress is suspected to play a key role in disease pathogenesis, complications and  
82 mortality [18-19] consequently, a number of studies have focused on the measurement of  
83 oxidative stress, many of which are through specific biomarkers that indicate the oxidative  
84 damage [20]. Lipid, protein and DNA biomolecules are the main targets of free radicals that

85 subsequently transformed into the reactive species reflecting oxidative stress in the  
86 corresponding molecules. Malondialdehyde (MDA), a product of lipid peroxidation, has been  
87 widely used as an indicator of oxidative stress. However, MDA measured by thiobarbituric acid  
88 assay overestimates actual MDA levels by more than 10-fold due probably to cross-reactivity  
89 with other aldehydes [21]. The isopentane, 8-iso-prostaglandin F<sub>2</sub>α (8-iso-PGF<sub>2</sub>α), is a more  
90 stable product of lipid peroxidation [22] and has been described at the gold standard  
91 biomolecule for assessing oxidative stress [23-24]. Measurement of 8-iso-PGF<sub>2</sub>α is a reliable  
92 tool for the identification of subjects with enhanced rates of lipid peroxidation [25].

93 In Africa, malaria and SCD are prevalent [26] and their co-morbidity have been reported in  
94 Ghana [27]. However, there is paucity of data on clinical manifestations, haematological profiles  
95 and degree of oxidative stress in SCD and malaria co-morbidities. Therefore, the aim of this  
96 study was to evaluate the variability of haematological parameters in malaria and SCD co-  
97 morbidities, identify novel cellular inflammatory biomarkers for predicting malaria in SCD and  
98 levels of 8-iso-PGF<sub>2</sub>α oxidative stress biomarker in Ghanaian sickle cell patients infected with  
99 malaria parasites.

## 100 **Materials and methods**

### 101 **Study site**

102 This multi-center study took place in 3 district hospitals and 3 health centers in the Greater  
103 Accra region of Ghana. The hospitals (latitude, longitude) were Ga West Municipal Hospital,  
104 Amasaman (5.7020708, -0.2992889), Ashaiman Polyclinic (5.6856, -0.0398) and Ada East

105 District Hospital (5.8956754, 0.5340865). The health centres (latitude, longitude) were Mayera  
106 Health Centre (5.720578, -0.2703561), Oduman Health Centre (5.64171, -0.3302) and Obom  
107 Health Centre (5.7361, -0.4395).

## 108 **Study design**

109 A cross-sectional study conducted in malaria suspected patients from November 2017-August,  
110 2018. The following clinical information; age, sex, temperature, body weight and clinical  
111 presentations was collected from each patient before sample collection. Maximum of three  
112 samples were collected each day from the study sites. 5ml of whole blood was collected from  
113 each consented patient. Specimens were transported from study sites to Ga West Municipal  
114 Hospital laboratory daily. Haematological profile was carried out on same day of sample  
115 reception. Blood films were prepared in triplicate. Screening for sickle cell and infectious  
116 makers were done, whole blood spun and plasma stored below -30°C. Haemolysate was  
117 prepared from concentrated red cell and kept frozen till ready for analysis.

## 118 **Study subjects, sample size and sample processing**

119 Figure 1 details participant recruitment plan used for the present study. Patients recruited for  
120 the study were physician suspected malaria cases. Sample size was determined based on single  
121 population formula using confidence interval of 95% and estimated proportion of 1 in 4 malaria  
122 infections occurring in sickle cell disease. The sample size was estimated to be 289.  
123 Measurement of 8-epi-prostaglandin F2 $\alpha$  biomarker was done in age and sex matched patients  
124 (normal controls n=40, malaria-HbAA n=40, SCD control n=40 and malaria-SCD n=40).

125 **Figure 1: Flow chart for sample collection and analysis.** Total of 2272 suspected malaria patients  
126 consented to participate in the study; microscopy did not detect malaria in 1858 (81.78%) of the  
127 patients while *Plasmodium falciparum* parasites were detected in 414 (18.22%) of the patients. Of the  
128 414 malaria patients, 12 (2.9%) had hepatitis B surface antigen (5), hepatitis C antibody (1), Salmonella  
129 typhi IgM (8) and HIV I&II antibodies (3) detected in their plasma. 5 triple infections were identified. Of  
130 the 402 malaria mono-infected patients, 112 (27.8%) were sickle cell positive; 67(60.0%) and 45(40.0%)  
131 were malaria in haemoglobin AS and haemoglobin SS/SC respectively. Prevalence of SCD and sickle cell  
132 trait (SCT) with malaria were 11.2% (45/402) and 16.6% (67/402) respectively. Excluding malaria in SCT  
133 from the study, the prevalence of malaria in SCD was computed to be 13.4% (45/335).  
134

## 135 **Inclusion and exclusion criteria**

136 Patients included in the study were microscopy diagnosed malaria patients, aged 0-20 years,  
137 who consented or whose parents consented to be part of the study. Individuals who were  
138 known SCD patients or visited the health centre on account of sickle cell crisis and malaria  
139 patients co-infected with hepatitis B virus, hepatitis C virus, syphilis and HIV 1&2 were  
140 excluded. Also samples with malaria and sickle cell trait were excluded.

## 141 **Laboratory analysis**

### 142 **Malaria detection and quantification**

143 Thick and thin blood film was done for each specimen, in triplicate, on the same glass slide. The  
144 dried thin film was fixed in absolute methanol briefly, air dried and stained with 10% Giemsa.  
145 The dried smear was then examined for presence of Plasmodium parasites. The parasites were  
146 subsequently identified to the species level and quantified per  $\mu\text{L}$  of blood and percentage RBC  
147 infected according WHO guidelines. Parasites were quantified per 200 WBCs counted using the  
148 patients' total WBC per  $\mu\text{L}$  of blood. A total of 500 WBCs were counted in negative infections

149 [28]. Each slide was double checked by a blinded certified malaria microscopist and in cases of  
150 discordant results; a third opinion was final.

### 151 **Infectious marker screening**

152 The specimens were screened for hepatitis B virus, hepatitis C virus, syphilis and HIV I&II  
153 pathogens to eliminate any possible effect on the haematological parameters. The  
154 microbiological screening was done with rapid immunochromatographic test kits. HIVI&II and  
155 syphilis were screened with First Response® test kit (Premier Medical Corporation Ltd, India)  
156 whilst the hepatitis B and C were screened with FaStep Rapid Diagnostic Test (Houston, USA).

### 157 **Haematological profiling**

158 Haematological profiling was done using Urit 5200 (China) fully automated haematology  
159 analyzer. The 5-part differential analyzer works on the principle of laser beam multi-  
160 dimensional cell classification flow cytometry for white cell differentiation, white and red blood  
161 cell estimation. Platelets were counted by optical and electrical impedance principles and  
162 haemoglobin concentration was measured by cyanide-free colorimetric method. All other  
163 parameters were calculated.

### 164 **Determination of leukocyte ratio cut-off values**

165 The 95% confidence interval (CI) was determined for each mean of the leukocyte ratios  
166 recorded in malaria-SCD. The upper or the lower value of the CI that majority of the individual  
167 values fell was taken as the cut-off value. The cut-off values were determined on ratio by ratio  
168 basis.



## 169 **Sickle cell screening and phenotyping**

170 Sickle cell screening was done by the sodium metabisulphite reduction method as previously  
171 described by Antwi-Baffour [29] Sickle cell phenotyping was done as described by  
172 Cheesborough [30]. Haemolysate was separated using electrophoresis in alkaline medium (pH  
173 8.6). Haemoglobin phenotyping was done alongside pooled HbA, HbS, HbC and HbF controls.  
174 Electrical voltage of 250 V and current of 50 mA were employed to obtain complete separation  
175 of haemoglobin variants for a maximum of 30 min. Results were read immediately against the  
176 controls.

## 177 **Sandwich-ELISA for 8-epi-prostaglandin F2 $\alpha$ levels**

178 Reagents and consumables for 8-epi-prostaglandin F2alpha was obtained from SunLong Biotech  
179 (Hangzhou, China, Catalogue Number: SL0035Hu). Measurement of 8-epi-prostaglandin  
180 F2alpha was done according to manufacturer's protocol, with these modifications; incubation  
181 of pre-diluted samples with coated anti-8-epi-prostaglandin F2 $\alpha$  and after addition of  
182 Horseradish Peroxidase-conjugated antibody specific for human 8-epi-prostaglandin F2alpha  
183 was done for 45 minutes at room temperature. Again, the chromogen solution was incubated  
184 for 30 minutes at room temperature after dispensing into the microelisa wells. The optical  
185 density (OD) was measured by Mindray MR-96A ELISA plate reader (Shenzhen, China) at a  
186 wavelength of 450 nm. The concentration of 8-epi-prostaglandin F2 $\alpha$  was obtained by  
187 comparing the OD of the samples to the standard curve.

## 188 **Statistical analysis**

189 Raw data were entered into Microsoft Excel 2010. Statistical analyses were done with Stata  
190 15.0 statistical software (Stata Corp LLC, USA). Pearson Chi square was used to determine  
191 differences in categorical data whilst differences in parametric variables were determined by t-  
192 test. To compare more than two groups, one-way ANOVA was used with multiple comparison  
193 undertaken using Tukey post hoc analysis. Correlation between variables was determined by  
194 Pearson correlation test. P-value <0.05 was considered statistically significant. Receiver  
195 operating characteristic (ROC) curve was used to estimate the sensitivity, specificity and  
196 predictive values of eosinophils-to-basophils and monocytes-to-basophils ratios to predict  
197 malaria in sickle cell disease.

## 198 **Results**

### 199 **Demographic, temperature and parasitemia in malaria and sickle cell** 200 **co-morbidity**

201 Patients with normal haemoglobin but infected with malaria (malaria-HbAA) formed the  
202 majority (86.6%; 290/335) of participants compared to malaria-SCD (13.43%; 45/335). Majority  
203 of the participants were females (55.8% females vs. 44.2% males). The mean age of malaria-  
204 HbAA was significantly higher than that of malaria-SCD patients (12.79±4.91 years vs 11.56±3.65  
205 years; p = 0.048). Body temperature was significantly higher in malaria-SCD than malaria-HbAA  
206 (37.9±1.15 vs. 39.0±0.87; t=6.86, p=0.001). The geometric mean of malaria parasite density  
207 was higher in malaria-HbAA (20394 parasites/μL, IQR 9519-51093) than malaria-SCD (9990  
208 parasites/μL, IQR 6329-16945) (table 1).

209 **Table 1: Demographic, temperature and parasitaemia of the patients**

Variables	Malaria-HbAA (n=290)	Malaria –SCD (n=45)	Statistic	p-value
Age (mean±SD)	12.79±4.91	11.56±3.65	t=2.01	0.048 <sup>a</sup>
Males, n (%)	127 (43.80)	21 (46.70)	X <sup>2</sup> =1.43	0.231 <sup>b</sup>
Females, n (%)	163 (56.20)	24 (53.30)		
Body temp range (mean ±SD)	37.9±1.15	39.0±0.87	t=6.89	<0.001 <sup>a</sup>
Parasite density range	223-620586	2492-112452		
GM of Parasite density	20394	9990	t=7.43	<0.001
Interquartile range	9519-51093	6329-16945		

210 <sup>a</sup> p-value determined by t-test, <sup>b</sup> p-value determined by Pearson Chi square, GM-Geometric  
 211 mean

## 212 **Haematological parameters in malaria and sickle cell co-morbidity**

213 The haematological variables of the participants were also compared (table 2). Whereas TWBC  
 214 (12.32±2.77 vs., 6.68±2.42 p=0.001), %lymphocytes (36.23±8.44 vs. 28.53±18.22, p=0.001),  
 215 %eosinophils (4.77±0.99 vs. 2.19±1.79, p=0.001) and %monocytes (7.32±1.58 vs. 5.92±3.30,  
 216 p=0.001) were significantly higher in malaria-SCD, %neutrophil (62.1 ±20.1 vs. 50.44±8.65,  
 217 p=0.001) and %basophils (0.45± 0.24 vs. 0.32±0.07, p=0.001) were significantly higher in  
 218 malaria-HbAA participants. Also, RBC count (4.22±0.78 vs. 3.87±0.69, p=0.001), haemoglobin  
 219 (9.19±1.06 vs. 10.83±2.11, p=0.001), haematocrit (27.34±2.79 vs. 31.84±6.07, p=0.001), MCV  
 220 (71.33 ±7.62 vs. 76.07±10.53, p=0.001) and MCH (24.53±4.09 vs. 25.89±3.78, p=0.041) were  
 221 significantly lower in malaria-SCD than malaria-HbAA. Although MCHC and RDW\_CV differed  
 222 among the participants, the differences did not reach statistical significance. Moreover,

223 platelets ( $190.0 \pm 55.30$  vs.  $138.71 \pm 87.70$ ,  $p=0.001$ ), MPV ( $10.78 \pm 1.28$  vs.  $9.91 \pm 1.40$ ,  $p=0.001$ ),  
 224 PDW ( $13.33 \pm 1.89$  vs.  $12.66 \pm 2.48$ ,  $p=0.038$ ), P\_LCR ( $30.21 \pm 7.39$  vs.  $25.11 \pm 8.06$ ,  $p=0.001$ ) were  
 225 significantly higher in malaria-SCD than malaria-HbAA.

226 **Table 2: Hematological parameters of malaria and sickle cell co-morbidity**

<b>Hematological parameters</b>	<b>Malaria-HbAA (mean±SD)</b>	<b>Malaria-SCD (mean±SD)</b>	<b>T value</b>	<b>p-value</b>
<b>White blood cells</b>	$6.68 \pm 2.42$	$12.32 \pm 2.77$	12.87	<0.001
<b>Neutrophils %</b>	$62.1 \pm 20.1$	$50.44 \pm 8.65$	6.65	<0.001
<b>Lymphocytes %</b>	$28.53 \pm 18.22$	$36.23 \pm 8.44$	4.66	<0.001
<b>Eosinophils %</b>	$2.19 \pm 1.79$	$4.77 \pm 0.99$	14.23	<0.001
<b>Monocytes %</b>	$5.92 \pm 3.30$	$7.32 \pm 1.58$	4.57	<0.001
<b>Basophils %</b>	$0.45 \pm 0.24$	$0.32 \pm 0.07$	7.79	<0.001
<b>Red blood cells</b>	$4.22 \pm 0.78$	$3.87 \pm 0.69$	3.07	<0.001
<b>Haemoglobin</b>	$10.83 \pm 2.11$	$9.19 \pm 1.06$	8.13	<0.001
<b>Haematocrit</b>	$31.84 \pm 6.07$	$27.34 \pm 2.79$	8.20	<0.001
<b>Mean Cell Volume</b>	$76.07 \pm 10.53$	$71.33 \pm 7.62$	3.66	<0.001
<b>Mean Cell Haemoglobin</b>	$25.89 \pm 3.78$	$24.53 \pm 4.09$	2.10	0.041
<b>MCHC</b>	$34.07 \pm 2.35$	$33.71 \pm 2.85$	0.80	0.426
<b>RDW_CV</b>	$14.29 \pm 1.78$	$14.48 \pm 1.68$	0.70	0.485
<b>RDW_SD</b>	$37.57 \pm 17.69$	$36.70 \pm 4.84$	0.69	0.492
<b>Platelets</b>	$138.71 \pm 87.70$	$190.0 \pm 55.30$	5.28	<0.001
<b>Mean Platelet Volume</b>	$9.91 \pm 1.40$	$10.78 \pm 1.28$	4.20	<0.001

<b>PDW</b>	12.66±2.48	13.33±1.89	2.12	0.038
<b>Plateletcrit</b>	0.18±0.88	0.17±0.07	0.23	0.817
<b>P_LCR</b>	25.11±8.06	30.21±7.39	4.65	<0.001

227 MCHC=Mean cell hemoglobin concentration, RDW\_CV=Red cell distribution width coefficient of  
 228 variation, RDW\_SD=Red cell distribution width standard deviation, L=Litre, fL=Fentolitre,  
 229 pg=pictogram, Plt=Platelets, PDW=Platelet distribution width, PCT=Plateletcrit, P\_LCR=Platelet  
 230 large cell ratio

231

### 232 **Variations in leukocyte ratios in malaria and sickle cell co-morbidities**

233 The mean leukocytes ratios observed in malaria-HbAA and malaria-SCD were significantly  
 234 different from each other (table 3). Lymphocytes-to-basophils ratio (76.10±66.33 vs.  
 235 125.19±59.30, p=0.001), eosinophils-to-monocytes ratio (0.43±0.65 vs. 0.68±0.21, p=0.001),  
 236 eosinophils-to-basophils ratio (4.62±2.52 vs. 16.05±5.64, p=0.001), monocytes-to-basophils  
 237 ratio (12.85±2.79 vs. 23.40±3.04, p=0.001) and platelets-to-neutrophils ratio (2.85±3.23 vs.  
 238 3.82± 1.04, p=0.001) were significantly higher in malaria-SCD. However, neutrophils-to-  
 239 lymphocytes ratio (3.82±3.86 vs. 1.51±0.55, p=0.001), neutrophils-to-eosinophils ratio  
 240 (13.08±5.87 vs. 11.30±4.22, p=0.001), neutrophils-to-monocytes ratio (16.97±25.18 vs. 7.25±  
 241 2.35, p=0.001), lymphocytes-to-eosinophils ratio (55.85±9.43 vs. 7.88±2.38, p=0.001),  
 242 lymphocytes-to-monocytes ratio (8.32±8.48 vs. 5.33± 2.27, p=0.009) and platelets-to-  
 243 lymphocytes ratio (7.16±6.80 vs. 5.63± 2.57, p=0.006) were significantly lower in malaria-SCD.

244 **Table 3: Leukocyte ratios among malaria and malaria-sickle cell co-morbidities**

<b>Leucocyte ratios</b>	<b>Malaria-HbAA</b>	<b>Malaria-SCD</b>	<b>T value</b>	<b>p-value</b>
	<b>(n=290)</b>	<b>(n=45)</b>		

Neutrophils-to-lymphocytes ratio	3.82±3.86	1.51±0.55	9.59	<0.001
Neutrophils-to-eosinophils ratio	13.08±5.87	11.30±4.22	5.62	<0.001
Neutrophils-to-monocytes ratio	16.97±25.18	7.25± 2.35	6.39	<0.001
Lymphocytes-to-eosinophils ratio	55.85±9.43	7.88± 2.38	4.19	<0.001
Lymphocytes-to-monocytes ratio	8.32±8.48	5.33± 2.27	2.63	0.009
Lymphocytes-to-basophils ratio	76.10±66.33	125.19±59.30	4.95	<0.001
Eosinophils-to-monocytes ratio	0.43±0.65	0.68±0 .21	4.87	<0.001
Eosinophils-to-basophils ratio	4.62±2.52	16.05±5.64	13.38	<0.001
Monocytes-to-basophils ratio	12.85±2.79	23.40±3.04	21.88	<0.001

245

## 246 **Predictive novel cellular inflammatory biomarkers in malaria in SCD**

247 In table 4 the leucocyte ratios were further explored for their ability to predict malaria-SCD  
 248 comorbidity by means of receiver operating characteristic (ROC). Neutrophils-to-monocytes  
 249 ratio was the most sensitive (93.33%, 95% CI: 81.73-98.60) but only 56.90% specific (95% CI: 50.98–  
 250 62.67) and had very low positive predictive value (PPV) (25.15%, 95% CI 22.37-28.15).  
 251 Lymphocytes-to-eosinophils ratio and lymphocytes-to-monocytes ratio were 86.67% and  
 252 80.00% sensitive respectively but not very specific (65.17% and 35.86% respectively) and had  
 253 very low PPV (27.86% and 16.22% respectively). The sensitivity, PPV and ROC of lymphocytes-  
 254 to-basophils ratio, neutrophils-to-eosinophils ratio and neutrophils-to-lymphocytes were  
 255 comparatively low. Eosinophils-to-basophils ratio (EBR) and monocytes-to-basophils ratio  
 256 (MBR) had relatively high predictive values. The cut-off values for EBR>14 and MBR>22  
 257 associated with malaria-SCD. The sensitivity, specificity, positive predictive value (PPV),

258 negative predictive value (NPV) and ROC of EBR>14 were 79.55% (95% CI: 64.70-90.20), 97.11%  
 259 (95% CI: 94.75-98.61), 77.78 % (95% CI: 65.11-86.78), 97.39 % (95% CI: 95.42-98.53) and 88.33%  
 260 (95% CI: 79.73-94.40). The values obtained for MBR>22 in predicting malaria in SCD were 84.09  
 261 % sensitive (95% CI: 69.93-93.36), 97.69 % specific (95% CI: 95.50-99.00), 82.22% PPV (95% CI  
 262 69.73-90.28), 97.97% NPV (95% CI: 96.07-98.96) and ROC value 90.89% (95% CI: 82.72-96.18).  
 263 When the combined performance of both EBR>14 and MBR>22 were analyzed, the obtained  
 264 values were higher than using either ERB>14 or MBR>20 alone. The following indices were thus  
 265 obtained for EBR>14-MBR>22; 91.11% sensitivity (95% CI: 78.78-97.52), 98.55% specificity (95%  
 266 CI: 96.66-99.53), 89.13% PPV (95% CI: 77.37-95.16), 98.84% NPV (95% CI: 97.10-99.54) and ROC  
 267 94.83% (95% CI 87.72-98.52). EBR and MBR were novel inflammatory markers found to be  
 268 significantly associated with malaria-SCD.

269 **Table 4: Novel leukocyte ratios associated with malaria-SCD**

<b>Inflammatory biomarker and cut-off value</b>	<b>Sensitivity 95% CI</b>	<b>Specificity 95% CI</b>	<b>PPV 95% CI</b>	<b>NPV 95% CI</b>	<b>ROC 95%CI</b>
<b>EBR&gt; 14</b>	79.55%	97.11%	77.78 %	97.39 %	88.33%
	64.70-90.20	94.75-98.61	65.11-86.78	95.42-98.53	79.73-94.40
<b>MBR&gt;22</b>	84.09 %	97.69 %	82.22 %	97.97 %	90.89%
	69.93-93.36	95.50-99.00	69.73-90.28	96.07-98.96	82.72-96.18
<b>EBR&gt;14-MBR&gt;22</b>	91.11%	98.55%	89.13%	98.84%	94. 83%
	78.78-97.52	96.66-99.53	77.37-95.16	97.10-99.54	87.72-98.52
<b>LBR&gt;107</b>	60.00	78.28	30.00	92.65	69.14
	44.33-74.30	73.08-82.88	23.67-37.20	89.77-94.77	58.71-78.59

<b>LER&lt;9</b>	86.67	65.17	27.86	96.92	75.92
	73.21-94.95	59.38-70.65	24.12-31.93	93.70-98.52	66.30-82.80
<b>LMR&lt;6</b>	80.00	35.86	16.22	92.04	57.93
	65.40-90.42	30.34-41.68	14.04-18.65	86.33-95.48	47.87-66.05
<b>NER&gt;10</b>	44.44	89.31	39.22	91.20	66.88
	29.64-60.00	85.17-92.62	28.81-50.70	88.83-93.10	57.40-76.31
<b>NLR&lt;1.7</b>	53.33	72.41	23.08	90.91	62.87
	37.87-68.34	66.89-77.48	17.73-29.46	87.89-93.23	52.38-72.91
<b>NMR&lt;8.0</b>	93.33	56.90	25.15	98.21	75.20
	81.73-98.60	50.98-62.67	22.37-28.15	94.83-99.40	66.36-80.64

270 CI-confidence interval; ROCV-receiver operating characteristic value; PPV-positive predictive  
 271 value; NPV-negative predictive value, EBR-eosinophils-to-basophils ratio, LBR-lymphocytes-to-  
 272 basophils ratio, LER-lymphocytes-to-eosinophils ratio, LMR-lymphocytes-to-monocytes ratio,  
 273 MBR-monocytes-to-basophils ratio, NER-neutrophils-to-eosinophils ratio, NLR-neutrophils-to-  
 274 lymphocytes ratio, NMR-neutrophils-to-monocytes ratio

## 275 **8-iso-prostaglandin F2 $\alpha$ levels and its correlates**

276 The oxidative stress associated with malaria infection and/or SCD inheritance were also  
 277 assessed through estimation of 8-iso-prostaglandin F2 $\alpha$  (table 5). The mean levels of 8-iso-  
 278 prostaglandin F2 $\alpha$  oxidative stress biomarker was significantly lower in control (no malaria-SCD  
 279 negative participants) compared to all other groups [84.1pg/ml vs 129.1pg/ml (SCD patients) vs  
 280 338.1pg/ml (malaria-HbAA) vs 643.8pg/ml (malaria-SCD); p = 0.001]. However, Tukey post hoc  
 281 analysis indicated non-significance difference between malaria-SCD and malaria-HbAA (t=1.13,  
 282 p=0.792). But pairwise post hoc analysis in the other groups were significant [(Malaria-SCD vs.  
 283 normal control, t=41.12, p=0.001), (Malaria-SCD vs. SCD, t=36.5, p=0.001), (Malaria-HbAA vs.



284 normal control,  $t=40.0$ ,  $p=0.001$ ), (Malaria-HbAA vs. SCD,  $t=35.38$ ,  $p=0.001$ ) and (SCD vs. normal  
 285 control,  $t=44.95$ ,  $p=0.001$ )]. Moreover, whereas 8-iso-prostaglandin F2 $\alpha$  was significantly  
 286 positively correlated with parasite density ( $r=0.787$ ,  $p=0.001$ ), temperature ( $r=0.566$ ,  $p=0.001$ )  
 287 and total WBC ( $r=0.573$ ,  $p=0.001$ ), it was inversely related to RBC ( $r=-0.476$ ,  $p=0.003$ ),  
 288 haemoglobin concentration ( $r=-0.851$ ,  $p=0.001$ ) and haematocrit ( $r=-0.735$ ,  $p=0.001$ ).

289 **Table 5: Analysis of 8-iso-prostaglandin F2 $\alpha$  and its correlation with haematological and other**  
 290 **parameters**

Variable	Control	SCD patients	Malaria-HbAA	Malaria-SCD	p-value
Age (years)	13.875(3.8)	14.125(3.7)	13.525(4.2)	13.575(3.7)	0.956 <sup>a</sup>
<b>Gender</b>					
Male	17(42.50)	20(50.00)	16(40.00)	18(45.00)	0.675 <sup>b</sup>
Female	23(57.50)	20(50.00)	24(60.00)	22(55.00)	
8-iso-PGF2 $\alpha$	84.1(16.3)	129.1(18.8)	338.1(50.2)	643.8(54.54)	<0.001 <sup>a</sup>
<b>8-iso-PGF2<math>\alpha</math> levels correlates with significant variables</b>				<b>r</b>	<b>p-value</b>
Parasite density				0.787	<0.001
Body temperature				0.566	<0.001
Red blood cells				-0.476	0.003
Haemoglobin				-0.851	<0.001
Haematocrit				-0.735	<0.001
Total WBC				0.573	<0.001

---

<sup>c</sup>Post hoc comparison of mean levels of 8-iso-prostaglandin F2 $\alpha$  oxidative stress biomarker

8-iso-prostaglandin F2 $\alpha$ levels	Tukey	
Tukey pairwise analysis	t	p-value
Malaria-SCD vs. malaria-HbAA	1.13	0.792
Malaria-SCD vs. normal control	41.12	<0.001
Malaria-SCD vs. SCD	36.50	<0.001
Malaria-HbAA vs. normal control	40.00	<0.001
Malaria-HbAA vs. SCD	35.38	<0.001
SCD vs. normal control	4.62	<0.001

---

291 <sup>a</sup>one-way-ANOVA; <sup>b</sup>Pearson chi square; <sup>c</sup>post-hoc analysis; abbreviations: 8-iso-PGF2 $\alpha$ -8-iso-  
292 prostaglandin F2 $\alpha$ ; SCD-sickle cell disease; Malaria-SCD-malaria-sickle cell disease co-morbidity

## 293 Discussion

294 In sub-Saharan Africa where inheritance of SCD is high and malaria infection is endemic, malaria  
295 and SCD comorbidity is prevalent in the general population. Malaria has been demonstrated to  
296 induce oxidant stress due to parasite multiplication as well as host immune response to the  
297 parasite [31]. In this study we show that inheritance of SCD alone or *P. falciparum* infection  
298 induces significant elevations in oxidant stress marker 8-iso-prostaglandin F2 $\alpha$ . Additionally, *P.*  
299 *falciparum* infection and SCD co-morbidity leads to synergistic increase of this oxidant stress  
300 biomarker in the peripheral blood of these patients.

301 The utility of 8-iso-prostaglandin F<sub>2</sub>α as oxidative stress biomarker indicated significant  
302 increases in malaria-HbAA, malaria-SCD and sickle cell patients compared to control subjects. 8-  
303 iso-prostaglandin F<sub>2</sub>α oxidative stress biomarker levels increased by 1.53, 4.0 and 7.6 folds in  
304 SCD, malaria-HbAA and malaria-SCD respectively. This finding is suggestive that 8-iso-  
305 prostaglandin F<sub>2</sub>α may be a useful oxidative stress biomarker in malaria and sickle cell patients.  
306 Interestingly levels of 8-iso-prostaglandin F<sub>2</sub>α in malaria-SCD comorbidity significantly  
307 correlated positively with parasite density, total WBC and body temperature and negatively  
308 with RBC, haemoglobin and haematocrit. As it has been demonstrated that increasing  
309 parasitemia leads to increased red cell destruction, elevated body temperature of patients and  
310 subsequent oxidant stress, the relationship between 8-iso-prostaglandin F<sub>2</sub>α and *P. falciparum*  
311 parasitemia reported herein is not surprising. The mean 8-iso-prostaglandin F<sub>2</sub>α in malaria-SCD  
312 patients was twice the mean 8-iso-prostaglandin F<sub>2</sub>α in malaria-HbAA patients. The observed  
313 differences could be attributed to cumulative effect of malaria infection in SCD. Previous study  
314 in Kenya found SCD to increase the severity of malaria [32]. This study could link this finding to  
315 excessive lipid peroxidation with the consequent elevation of 8-iso-prostaglandin F<sub>2</sub>α. There is  
316 limited data on the use of 8-iso-prostaglandin F<sub>2</sub>α oxidative to assess oxidative stress in SCD  
317 even though previous works have assessed oxidative stress using nitric Oxide (NO), superoxide,  
318 peroxide, hydroxyl radicals [33, 34] and malondialdehyde (MDA) [33, 35-37]. The use 8-iso-  
319 prostaglandin F<sub>2</sub>α to assess oxidative stress in malaria is not popular, though 8-iso-  
320 prostaglandin F<sub>2</sub>α is currently the gold standard for the assessment of oxidative stress in  
321 disease conditions [23, 24]. Oxidative stress due to reactive oxygen species (ROS) activity on  
322 MDA has been implicated previously in the pathogenesis and complications in malaria. It has

323 been established that Falciparum infected human RBCs are under constant oxidative stress [38]  
324 due to generation of ROS within erythrocytes infected cells and also from immune activation  
325 [39, 40].

326 Previous study done in Ghana in patients below 20 years, reported that WBC and lymphocytes  
327 in malaria patients were lower compared to control subjects. The other leucocytes sub-types  
328 were not significantly different from control subjects [41]. However, the current study observed  
329 significantly high leucocytes and leucocytes sub-types derangements in malaria-SCD except  
330 neutrophils and basophils. Presentations of observed symptoms in malaria-SCD could be  
331 related to the actions of pro-inflammatory cytokines with mononuclear cells having been  
332 implicated as a key player [42]. This study found two novel cellular inflammatory biomarkers,  
333 namely eosinophils-to-basophils ratio (EBR) and monocytes-to-basophils ratio (MBR), as being  
334 associated with malaria-SCD. EBR>14 and MBR>22 and combination of the two, EBR>14-  
335 MBR>22, could be used to predict malaria in sickle cell disease. The sensitivity of EBR>14-  
336 MBR>22 was 11.56% and 7.02% higher than EBR>14 and MBR>22 when compared individually.  
337 The specificity and negative predictive values of the novel biomarkers were greater than 90%;  
338 this makes them very specific in excluding malaria in sickle cell disease. The ROCV obtained  
339 makes the diagnostic use of EBR>14-MBR>22 better than EBR>14 and MBR>22. As leukocyte  
340 ratios have been widely suggested to predict both communicable and non-communicable  
341 diseases [43-45], our findings are suggestive of potential roles in *P. falciparum* pathophysiology.

342 In malaria-SCD, haemoglobin, hematocrit, mean cell haemoglobin and mean cell volume were  
343 significantly reduced in a similar fashion as seen in microcytic and hypochromic anaemia. The

344 reductions in RBC and red cell indices associated with malaria-SCD could probably be due to  
345 cumulative effect of increased rate of haemolysis during oxygenation and deoxygenation  
346 process, reduced response to erythropoietin secretion in sickle cell anemia together with acute  
347 malaria infections [46]. Significant elevations were observed in platelets, mean platelet volume,  
348 platelet distribution width and plateletcrit in malaria-SCD patients. Relative thrombocytopenia  
349 was seen in the malaria-HbAA patients. Malaria-related case vs. control thrombocytopenia has  
350 been reported in several studies [6, 47-48]. Elevation in platelets and platelet indices suggests  
351 efficient haemostasis in malaria-SCD than malaria infections in the absence of SCD.

## 352 **Conclusion**

353 EBR>14 and MBR>22 were novel cellular inflammatory biomarkers found to be associated with  
354 malaria-SCD and can possibly be employed in the diagnosis of this co-morbidity. Additionally,  
355 malaria-SCD levels of 8-iso-prostaglandin F2 $\alpha$  oxidative stress biomarker was twice as observed  
356 in malaria-HbAA.

## 357 **List of abbreviations**

358 ANOVA-one way analysis of variance; EBR-eosinophils-to-basophils ratio; ELISA-enzyme lined  
359 immuno-sorbent assay; EMR-eosinophils-to-monocytes ratio; HbS-Sickle cell hemoglobin; HbSS-  
360 two HbS haplotypes; LBR-lymphocytes-to-basophils ratio; LER-lymphocytes-to-eosinophils ratio;  
361 LMR-lymphocytes-to-monocytes ratio (LMR); malaria-HbAA- malaria in normal hemoglobin;  
362 malaria-SCD-malaria in sickle cell disease; MDA-malondialdehyde; MBR-monocytes-to-basophils  
363 ratio; MCH-mean cell hemoglobin; MCV-mean cell volume; NBR-neutrophils-to-basophils ratio;  
364 NER-neutrophils-to-eosinophils ratio; NLR-neutrophils-to-lymphocytes ratio; NMR-neutrophils-  
365 to-monocytes ratio; OD-optical density; PNR-platelet-to-neutrophils ratio; ROC-receiver  
366 operating characteristic; SCD-Sickle cell disease; SCT-sickle cell trait; SSA-Sub-Saharan Africa;  
367 TBAA-thiobarbituric acid assay

## 368 **Ethical approval**

369 Ethical approval for this study was granted by Ghana Health Service Ethics Review Committee  
370 (Approval No: GHS-ERC002/03/18). Participant consent was sought for participant.  
371

## 372 **Raw data**

373 All relevant data are within the paper.

## 374 **Acknowledgements**

375 We acknowledge Michael Ankwadah, Michael Gyimah, Sedem Bokor, Bridgette Tevi and Alex  
376 Nyarko for the role they played in recruiting the patients, collection of clinical data and taking  
377 specimens for the study. We are also grateful to Nicholas Sowa for his immense contributions  
378 during the laboratory measurement of the 8-iso-prostaglandin F2 $\alpha$  oxidative stress biomarker.

## 379 **Authors' contributions**

380 EA, PA, DOA, RKDE conceptualized, designed and coordinated the study. EA, EDT, PA performed  
381 the statistical analysis and JB, EN participated in the sample collection and processing. AE, PA  
382 drafted the manuscript, manuscript proofread by RKDE, AE-Y which was later approved by all  
383 authors

## 384 **References**


- 385 1. Kelkar DS, Patnaik MM, Joshi SR. Malarial Hematopathy. *J Assoc Physicians India.*  
386 2004;52:6114
- 387 2. Niazi GA. Haematological aspect of malaria in a population based hospital, Saudi Arabia.  
388 *J Egypt Soc Parasitol.* 1995; 25:787-93.
- 389 3. Rojanasthien S, Surakamollearat V, Boonpucknavig S, Isarangkura P. Hematological and  
390 coagulation studies in malaria. *J Med Assoc Thai.* 1992; 75 Suppl 1:190-4
- 391 4. Bashawri LAM, Mandil AA, Bahnassy AA, Ahmed MA. Malaria: Haematological Aspects.  
392 *Ann Saudi Med.* 2002;22:372-77.
- 393 5. Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirkjaroen\_\_L, Kuile FT,  
394 Chongsuphajaisiddhi T, White NJ. Factors contributing to anemia after uncomplicated  
395 falciparum malaria. *Am J Trop Med Hyg.* 2001;65:614–622.
- 396 6. Erhart LM, Yingyuen K, Chuanak N, Buathong N, Laoboonchai A, Miller RS, Meshnick SR,  
397 Gasser Jr RA, Wongsrichanalai C. Hematologic and clinical indices of malaria in a semi-  
398 immune population of Western Thailand. *Am J Trop Med Hyg.* 2004;70:8–14.
- 399 7. Ghana Health Service, January to December, 2016. Ghana Malaria Control Programme  
400 Periodic Bulletin. 2016;8:1-15.

- 401 8. Konotey-Ahulu FID. The Sickle Cell Disease Patient. 1<sup>st</sup> ed. London: Macmillan; 1991
- 402 9. Odievre MH, Verger E, Silva-Pinto AC, Elion J. Pathophysiological insights in sickle cell
- 403 disease. *Indian J Med Res.* 2011;134:532-7
- 404 10. Jadhav AJ, Vaidya SM, Bhagwat VR, Ranade AR, Vasaikar M. Haematological profile of
- 405 adult sickle cell disease patients in North Maharashtra. *WIMJOURNAL.* 2016;3:1.
- 406 11. Kohchale SR, Raja IA. Hematological Profile of Sickle Cell Anemic Subjects from
- 407 Gadchiroli District, Maharashtra. *International J of Life Sciences.* 2015;153-156.
- 408 12. Rao SS, Goyal JP, Raghunath SV, Shah VB. Hematological profile of sickle cell disease
- 409 from South Gujarat, India. *Hematology Reports.* 2012; volume 4:e8
- 410 13. Singh U, Jialal I. Oxidative stress and atherosclerosis. *Pathophysiology* 2006;13:129-42
- 411 14. Kulkarni AG, Suryakar AN, Sardeshmukh AS, Rathi DB. Studies on biochemical changes
- 412 with special reference to oxidant and anti-oxidants in malaria patients. *Ind J Clin*
- 413 *Biochem.* 2003;18:136–49.
- 414 15. Das BS, Nanda NK. Evidence for erythrocyte lipid peroxidation in acute falciparum
- 415 malaria. *Trans Roy Soc. Trop Med Hyg* 1999;93: 58-62
- 416 16. Stuart MJ, Nagel RL. Sickle-cell disease. *Lancet.* 2004;364(9442): 1343-60. Comment in:
- 417 *Lancet.* 2005;365(9457):382-3.
- 418 17. Belcher JD, Beckman JD, Balla G, Balla J, Vercellotti G. Heme degradation and vascular
- 419 injury. *Antioxid Redox Signal.* 2010;12(2):233-48.
- 420 18. Ozkul A, Akyol A, Yenisey C, Arpacı E, Kiylioglu N, Tataroglu C. Oxidative stress in acute
- 421 ischemic stroke. *J Clin Neurosci.* 2007; 14, 1062–1066.
- 422 19. Bauer M, Grabsch C, Schlink U, Klopp N, Illig T, Kramer U, von Berg A, Schaaf B, Borte M,
- 423 Heinrich J, Herbarth O, Lehmann I, Roder S. Genetic association between obstructive
- 424 bronchitis and enzymes of oxidative stress. *Metabolism.* 2012; 61:1771–1779.
- 425 20. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of Oxidative
- 426 Damage in Human Disease. *ClinChem.* 2006; 52:601–623.
- 427 21. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in
- 428 atherothrombotic disease. *Arterioscler Thromb Vasc Biol.* 1997;17:2309-15.
- 429 22. Wang B, Pan J, Wang L, Zhu H, Yu R, Zou Y. Associations of plasma 8-isoprostane levels
- 430 with the presence and extent of coronary stenosis in patients with coronary artery
- 431 disease. *Atherosclerosis.* 2006;184: 425-30.
- 432 23. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, Nyska A,
- 433 Wachsman JT, Ames BN, Basu S, Brot N, Fitzgerald GA, Floyd RA, George M, Heinecke
- 434 JW, Hatch GE, Hensley K, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plataras J,
- 435 Roberts LJ II, Rokach J, Shigenaga MK, Sohal RS, Sun J, Tice RR, Van Thiel DH, Wellner D,
- 436 Walter PB, Tomer KB, Mason RP, Barrett J. Biomarkers of oxidative stress study II: are
- 437 oxidation products of lipids, proteins, and DNA markers of CCl<sub>4</sub> poisoning? *Free Radic*
- 438 *Biol Med.* 2005;38:698–710.
- 439 24. Kadiiska MB, Gladen BC, Baird DD, Graham LB, Parker CE, Ames BN, Basu S, Fitzgerald
- 440 GA, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plataras J, Roberts LJ II, Rokach J,
- 441 Shigenaga MK, Sun J, Walter PB, Tomer KB, Barrett JC, Mason RP. Biomarkers of
- 442 oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents

- 443 indomethacin and meclofenamic acid on measurements of oxidative products of lipids  
444 in CCl<sub>4</sub> poisoning. *Free Radic Biol Med.* 2005;38:711–718.
- 445 25. Schwedhelm E, Bartling A, Lenzen H, Tsikakos D, Maas R, Brümmer J, Gutzki FM, Berger  
446 J, Frölich JC, Böger RH. Urinary 8-iso-prostaglandin F<sub>2</sub>α as a risk marker in patients  
447 with coronary heart disease: a matched case-control study. *Circulation* 2004;109:843-8.
- 448 26. Ohene-Frempong K, Oduro J, Tetteh H, Nkrumah F. Screening newborns for sickle cell  
449 disease in Ghana. *Pediatrics.* 2008;121(Suppl 2):S120-S121.
- 450 27. Fisher AE, Oduro AKY, Adzaku F, Telfer P. Presentations of sickle cell disease patients to  
451 hospital in Ghana: key findings from a preliminary study at Volta Regional Hospital.  
452 *British Journal of Haematology.* 2017;178:476–491.
- 453 28. World Health Organization. Routine examination of blood films for malaria parasites. In:  
454 World Health Organization, editor. *Basic Malaria Microscopy, Learner’s guide.*  
455 Switzerland: WHO 2010;69–76.
- 456 29. Antwi-Baffour S, Asare RO, Adjei JK, Kyeremeh R, Adjei DN. Prevalence of hemoglobin S  
457 trait among blood donors: a cross-sectional study. *BMC Res Notes.* 2015;8:583.
- 458 30. Cheesbrough M. Haematological tests: abnormal haemoglobins. In: *District laboratory*  
459 *practice in tropical countries. Part 2, 2nd ed.* Cambridge Universal Press, New York; 2006
- 460 31. Postma NS, Mommers EC, Eling WM & Zuidema J. Oxidative stress in malaria;  
461 implications for prevention and therapy. *Pharm World Sci.* 1996;18, 121–129
- 462 32. Komba AN, Makani J, Sadarangani, Agbo TA, Berkley JA, Newton CRJC, Marsh K, Williams  
463 TN. Malaria as a cause of morbidity and mortality in children with homozygous sickle cell  
464 disease on the coast of Kenya. *Clin Infect Dis.* 2009; 49:216–22.
- 465 33. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical  
466 generation by sickle erythrocytes. *J Clin Invest.* 1982;70(6):1253-9.
- 467 34. Adelekan DA, Thurnham DI, Adekile AD. Reduced antioxidant capacity in paediatric  
468 patients with homozygous sickle cell disease. *Eur J Clin Nutr.* 1989; 43(9):609-14.
- 469 35. Giera M, Lingeman H, Niessen WM. Recent Advancements in the LC- and GC-Based  
470 Analysis of Malondialdehyde (MDA): A Brief Overview. *Chromatographia.* 2012;75(9-  
471 10):433-440.
- 472 36. Titus J, Chari S, Gupta M, Parekh N. Pro-oxidant and anti-oxidant status in patients of  
473 sickle cell anaemia. *Indian J Clin Biochem.* 2004;19:168–72.
- 474 37. Das SK, Nair RC. Superoxide dismutase, glutathione peroxidase, catalase and lipid  
475 peroxidation of normal and sickled erythrocytes. *Br J Haematol.* 1980;44:87–92.
- 476 38. Golenser J, Marva E, Chevion M. The survival of Plasmodium under oxidant stress,  
477 *Parasitology Today.* 1991;7:142-146.
- 478 39. Rath RN, Panigrahi N, Das BK, Das PK. Lipid peroxidation in acute falciparum malaria. *Ind*  
479 *J Med Res.* 1991;93:303-305.
- 480 40. Amy M, Gelasius M, Anuraj US, Grace N, George M, Richard DS. Antioxidant status and  
481 acute malaria in children in Kampala Uganda. *Am J Trop Med Hyg.* 2001;65:115-119.
- 482 41. Squire DS, Asmah, RH, Brown CA, Adjei DN, Obeng-Nkrumah N, Ayeh-Kumi PF. Effect of  
483 Plasmodium falciparum malaria parasites on haematological parameters in Ghanaian  
484 children *J Parasit Dis.* 40(2):303–311



- 485 42. Muller-Steinhardt M, Ebel B, Hartel C. The impact of interleukin-6 promoter -597/-572/-  
486 174genotype on interleukin-6 production after lipopolysaccharide stimulation. Clin Exp  
487 immuno. 2007;147(2):339–45. Epub 2007/01/17.
- 488 43. Hao R, Xiao L, Lin W, Yanjun G. Lymphocyte-to-Monocyte Ratio: A Novel Predictor of the  
489 Prognosis of Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2017:2595–2602.
- 490 44. Durmus E, Tarik K, Fethullah G, Murat S, Ibrahim S, Okan E. Neutrophil-to-Lymphocyte  
491 Ratio and Platelet-to-Lymphocyte Ratio are Predictors of Heart Failure. Arq Bras Cardiol.  
492 2015;105(6):606-613
- 493 45. Pinar S, Tuna D, Atakan N, Ilknur V, Mehmet K, Atilla S. The Significance of Neutrophil to  
494 Lymphocyte Ratio and the Other Infection Markers on Predicting Bacteremia and  
495 Prognosis in Patients Diagnosed With Systemic Inflammatory Response Syndrome (SIRS)  
496 and Sepsis in Intensive Care Unit. Open Forum Infectious Diseases. 2016;  
497 3(1043),<https://doi.org/10.1093/ofid/ofw172.746>
- 498 46. Adebola OA. Haematological values in homozygous sickle cell disease in steady state and  
499 haemoglobin phenotypes AA controls in Lagos, Nigeria. BMC Research Notes  
500 2012;5:396.DOI: 10.1186/1756-0500-5-396.
- 501 47. Maina RN, Walsh D, Gaddy C, Hongo G, Waitumbi J, Otieno L, Jones D, Ogutu BR. Impact  
502 of *Plasmodium falciparum* infection on haematological parameters in children living in  
503 Western Kenya. Malar J. 2010; 9(Suppl 3):S4.
- 504 48. Senthilkumaar P, Sarojini S. Haematological studies in malaria affected patients in North  
505 Chennai, Tamil Nadu. Euro J Exp Bio. 2013;3:199-205.



Figure